Penumbra (PEN) Stock Faces Q3 Earnings Valuation Scrutiny
Published . Updated .
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
This report does not map to a usual set of affected companies.
Directly affected
- PEN Penumbra+1.0% 30d
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that Penumbra belongs to, so it often moves with news about it.
- SYK Stryker+16.7% 30d
Stryker is a peer of Penumbra in surgical and medical instruments and apparatus; rivals often move on the same news.
- MMM 3M+15.1% 30d
3M is a peer of Penumbra in surgical and medical instruments and apparatus; rivals often move on the same news.
- BSX Boston Scientific+3.8% 30d
Boston Scientific is a peer of Penumbra in surgical and medical instruments and apparatus; rivals often move on the same news.
- BDX Becton, Dickinson and+19.7% 30d
Becton, Dickinson and is a peer of Penumbra in surgical and medical instruments and apparatus; rivals often move on the same news.
- MDLN Medline+9.3% 30d
Medline is a peer of Penumbra in surgical and medical instruments and apparatus; rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| PEN | +1.99% | -0.14% | base | +0.80% | +0.41% | +1.18% | +0.77% |
| XLV | -3.03% | -2.77% | base | -0.14% | -0.48% | +2.59% | +0.17% |
| SYK | +5.10% | +4.38% | base | +5.34% | +6.53% | +16.59% | +14.97% |
| MMM | -0.88% | -0.89% | base | +2.34% | +1.58% | +11.32% | +7.71% |
| BSX | +8.65% | +1.02% | base | +5.62% | +3.65% | +9.15% | +6.31% |
| BDX | -0.73% | -1.34% | base | +0.39% | +0.20% | +5.67% | +7.90% |
| MDLN | +4.92% | +0.90% | base | +4.80% | +6.26% | +25.81% | +23.96% |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Penumbra (PEN) Stock Faces Q3 Earnings Valuation Scrutiny Yahoo Finance
Source: Yahoo Finance
This story
| Company | When | Move | Status |
|---|---|---|---|
| BDX | that day | +0.39% | final price |
| BDX | the next day | +0.20% | final price |
| BDX | two days later | +5.67% | final price |
| BDX | three days later | +7.90% | final price |
| BDX | three days earlier | -1.34% | final price |
| BDX | five days earlier | -0.73% | final price |
| BSX | that day | +5.62% | final price |
| BSX | the next day | +3.65% | final price |
| BSX | two days later | +9.15% | final price |
| BSX | three days later | +6.31% | final price |
| BSX | three days earlier | +1.02% | final price |
| BSX | five days earlier | +8.65% | final price |
| MDLN | that day | +4.80% | final price |
| MDLN | the next day | +6.26% | final price |
| MDLN | two days later | +25.81% | final price |
| MDLN | three days later | +23.96% | final price |
| MDLN | three days earlier | +0.90% | final price |
| MDLN | five days earlier | +4.92% | final price |
| MMM | that day | +2.34% | final price |
| MMM | the next day | +1.58% | final price |
| MMM | two days later | +11.32% | final price |
| MMM | three days later | +7.71% | final price |
| MMM | three days earlier | -0.89% | final price |
| MMM | five days earlier | -0.88% | final price |
| PEN | that day | +0.80% | final price |
| PEN | the next day | +0.41% | final price |
| PEN | two days later | +1.18% | final price |
| PEN | three days later | +0.77% | final price |
| PEN | three days earlier | -0.14% | final price |
| PEN | five days earlier | +1.99% | final price |
| SYK | that day | +5.34% | final price |
| SYK | the next day | +6.53% | final price |
| SYK | two days later | +16.59% | final price |
| SYK | three days later | +14.97% | final price |
| SYK | three days earlier | +4.38% | final price |
| SYK | five days earlier | +5.10% | final price |
| XLV | that day | -0.14% | final price |
| XLV | the next day | -0.48% | final price |
| XLV | two days later | +2.59% | final price |
| XLV | three days later | +0.17% | final price |
| XLV | three days earlier | -2.77% | final price |
| XLV | five days earlier | -3.03% | final price |
Congressional trades in the stocks in this story
- Rep. Thomas H. Kean Jr sold Stryker (SYK), worth $1,001 - $15,000 on 30 Sep 2026. That is 31 days before publication. Filed 30 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Stryker (SYK) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 36 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Stryker (SYK) (held by a dependent child), worth $15,001 - $50,000 on 11 Sep 2026. That is 50 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Kevin Hern sold Boston Scientific (BSX) (jointly held), worth $50,001 - $100,000 on 9 Sep 2026. That is 52 days before publication. Filed 25 Sep 2026. View the filing.
- Rep. Kevin Hern sold Boston Scientific (BSX) (jointly held), worth $50,001 - $100,000 on 4 Sep 2026. That is 57 days before publication. Filed 25 Sep 2026. View the filing.
- Rep. Kevin Hern sold Boston Scientific (BSX) (held by a dependent child), worth $1,001 - $15,000 on 3 Sep 2026. That is 58 days before publication. Filed 25 Sep 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
How solid “Penumbra (PEN) Stock Faces Q3 Earnings Valuation Scrutiny” looks
12 out of 100
“Penumbra (PEN) Stock Faces Q3 Earnings Valuation Scrutiny” scores 12 out of 100. The score uses 1 sources.